PLAINSBORO, N.J., Dec. 8 /PRNewswire/ -- Integra LifeSciences Corporation (Nasdaq: IART) today announced that it has received approval from the Medical Device Administration of the People's Republic of China to import and market INTEGRA(TM) Artificial Skin throughout the country. The Chinese import certification is for use in burns as well as plastic and reconstruction surgery procedures. INTEGRA Artificial Skin is now commercially marketed in some 20 countries including the U.S. and Canada. The use of INTEGRA enables the body to regenerate its own permanent dermal tissue.
The Company has already sponsored three lectures introducing the medical application of INTEGRA Artificial Skin to some 200 doctors and nurses from more than 30 different cities in China. The Company believes that the potential annual market in China could range between $25 million and $30 million.
In addition to China, the other countries include, Taiwan, New Zealand, Australia, United Kingdom, Ireland, Hong Kong, Singapore, France, Thailand, Sweden, Netherlands, Norway, Finland, Switzerland, Israel, Denmark, and certain states in Germany on an individual patient basis. The international market accounts for approximately 25 percent to 30 percent of INTEGRA overall sales.
"Given the volume of approvals and market potential of the international market, which could be twice that of the United States, the Company has reason to be deeply pleased," said Andre Decarie, Senior Vice President of Business Development. "The company's ISO-9001 certification cleared a major hurdle for us toward obtaining the CE Mark (European Community regulatory approval), which will continue to broaden our overall sales."
For a menu of Integra LifeSciences Corporation press releases or to retrieve a specific release, call 800-758-5804, extension 106047 or prnewswire.com on the Internet.
|
